CYCLACEL PHARMACEUTICALS, INC. (NASDAQ:CYCC) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
(e)On June 27, 2017, the Compensation and Organization
Development Committee of Cyclacel Pharmaceuticals, Inc. (the
Company) approved the extension of the
employment agreements (each, an Employment
Agreement being extended by an Extension
Agreement) with Spiro Rombotis, the President and Chief
Executive Officer of the Company, and Paul McBarron, the
Executive Vice President-Finance, Chief Financial Officer and
Chief Operating Officer of the Company, such Extension Agreements
to be effective as of July 1, 2017.
The terms of Mr. Rombotiss Employment Agreement, which were
previously disclosed under cover of Current Reports on Form 8-K
filed on March 21, 2008, December 14, 2010, March 21, 2014,
remain unchanged, except that the term has been extended for
another six months, through December 31, 2017.
The terms of Mr. McBarrons Employment Agreement, which were
previously disclosed under cover of Current Reports on Form 8-K
filed on April 2, 2008, December 14, 2010, and March 21, 2014,
remain unchanged, except that the term has been extended for
another six months, through December 31, 2017.
Copies of the Extension Agreements are filed as Exhibits 10.1 and
10.2 hereto and are incorporated by reference.
| Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits.
| Exhibit Number | Description | |
|
10.1 |
Employment Extension Agreement by and between Cyclacel |
|
| 10.2 |
Employment Extension Agreement by and between Cyclacel Pharmaceuticals, Inc. and Paul McBarron, dated as of June 27, 2017. |
Cyclacel Pharmaceuticals, Inc. ExhibitEX-10.1 2 v469810_ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 CYCLACEL PHARMACEUTICALS,…To view the full exhibit click here About CYCLACEL PHARMACEUTICALS, INC. (NASDAQ:CYCC)
Cyclacel Pharmaceuticals, Inc. operates in the field of cell cycle biology. The Company has generated various families of anticancer drugs that act on the cell cycle, including nucleoside analogs, cyclin dependent kinase (CDK) inhibitors, polo-like kinase (PLK) inhibitors and Aurora Kinase/vascular endothelial growth factor receptor (AK/VEGFR) inhibitors. Its family of anticancer drugs that act on the cell cycle include sapacitabine, seliciclib and CYC065. Its lead candidate, sapacitabine, is an orally available nucleoside analog. A number of nucleoside drugs, such as gemcitabine and cytarabine, also known as Ara-C, both generic drugs, are in use as conventional chemotherapies. Seliciclib, its lead CDK inhibitor, is an oral inhibitor of CDK2/9 enzymes that are central to the process of cell division and cell cycle control. Its second-generation CDK inhibitor, CYC065, is an inhibitor of CDKs targeting CDK2/9 enzymes with utility in both hematological malignancies and solid tumors.
